Severe Asthma

David L. Rosenstreich, MD; Joan Reibman, MD


March 24, 2020

Asthma afflicts more than 25 million Americans, a number that has been increasing since the early 1980s in all age, sex, and racial groups. Uncontrolled asthma not only affects quality of life but disproportionately increases healthcare utilization and morbidity.

Current guideline-directed treatment focuses on a stepwise approach consisting of increasing doses of medications, primarily inhaled corticosteroids. Despite adherence to such therapies, many patients with moderate to severe asthma still experience symptoms and exacerbations.

In this panel ReCAP, Drs David Rosenstreich and Joan Reibman discuss the important distinction between severe and hard-to-control asthma, and explore the effective use of newer biologic therapies in this patient population. With three classes of biologics each acting against specific targets, the physicians consider factors for choosing appropriate therapies for individual patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.